Literature DB >> 24807083

A multicenter study of septic shock due to candidemia: outcomes and predictors of mortality.

Matteo Bassetti1, Elda Righi, Filippo Ansaldi, Maria Merelli, Cecilia Trucchi, Trucchi Cecilia, Gennaro De Pascale, Ana Diaz-Martin, Roberto Luzzati, Chiara Rosin, Leonel Lagunes, Enrico Maria Trecarichi, Maurizio Sanguinetti, Brunella Posteraro, Jose Garnacho-Montero, Assunta Sartor, Jordi Rello, Giorgio Della Rocca, Massimo Antonelli, Mario Tumbarello.   

Abstract

PURPOSE: Candida is the most common cause of severe yeast infections worldwide, especially in critically ill patients. In this setting, septic shock attributable to Candida is characterized by high mortality rates. The aim of this multicenter study was to investigate the determinants of outcome in critically ill patients with septic shock due to candidemia.
METHODS: This was a retrospective study in which patients with septic shock attributable to Candida who were treated during the 3-year study period at one or more of the five participating teaching hospitals in Italy and Spain were eligible for enrolment. Patient characteristics, infection-related variables, and therapy-related features were reviewed. Multiple logistic regression analysis was performed to identify the risk factors significantly associated with 30-day mortality.
RESULTS: A total of 216 patients (mean age 63.4 ± 18.5 years; 58.3 % males) were included in the study. Of these, 163 (75 %) were admitted to the intensive care unit. Overall 30-day mortality was 54 %. Significantly higher Acute Physiology and Chronic Health Evaluation (APACHE) II scores, dysfunctional organs, and inadequate antifungal therapy were compared in nonsurvivors and survivors. No differences in survivors versus nonsurvivors were found in terms of the time from positive blood culture to initiation of adequate antifungal therapy. Multivariate logistic regression identified inadequate source control, inadequate antifungal therapy, and 1-point increments in the APACHE II score as independent variables associated with a higher 30-day mortality rate.

Entities:  

Mesh:

Year:  2014        PMID: 24807083     DOI: 10.1007/s00134-014-3310-z

Source DB:  PubMed          Journal:  Intensive Care Med        ISSN: 0342-4642            Impact factor:   17.440


  26 in total

1.  Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: a multi-institutional study.

Authors:  Kevin W Garey; Milind Rege; Manjunath P Pai; Dana E Mingo; Katie J Suda; Robin S Turpin; David T Bearden
Journal:  Clin Infect Dis       Date:  2006-05-16       Impact factor: 9.079

2.  ESCMID* guideline for the diagnosis and management of Candida diseases 2012: non-neutropenic adult patients.

Authors:  O A Cornely; M Bassetti; T Calandra; J Garbino; B J Kullberg; O Lortholary; W Meersseman; M Akova; M C Arendrup; S Arikan-Akdagli; J Bille; E Castagnola; M Cuenca-Estrella; J P Donnelly; A H Groll; R Herbrecht; W W Hope; H E Jensen; C Lass-Flörl; G Petrikkos; M D Richardson; E Roilides; P E Verweij; C Viscoli; A J Ullmann
Journal:  Clin Microbiol Infect       Date:  2012-12       Impact factor: 8.067

3.  Delaying the empiric treatment of candida bloodstream infection until positive blood culture results are obtained: a potential risk factor for hospital mortality.

Authors:  Matthew Morrell; Victoria J Fraser; Marin H Kollef
Journal:  Antimicrob Agents Chemother       Date:  2005-09       Impact factor: 5.191

4.  Inflammatory response and clinical course of adult patients with nosocomial bloodstream infections caused by Candida spp.

Authors:  H Wisplinghoff; H Seifert; R P Wenzel; M B Edmond
Journal:  Clin Microbiol Infect       Date:  2006-02       Impact factor: 8.067

5.  International study of the prevalence and outcomes of infection in intensive care units.

Authors:  Jean-Louis Vincent; Jordi Rello; John Marshall; Eliezer Silva; Antonio Anzueto; Claude D Martin; Rui Moreno; Jeffrey Lipman; Charles Gomersall; Yasser Sakr; Konrad Reinhart
Journal:  JAMA       Date:  2009-12-02       Impact factor: 56.272

6.  Epidemiology, management, and risk factors for death of invasive Candida infections in critical care: a multicenter, prospective, observational study in France (2005-2006).

Authors:  Olivier Leroy; Jean-Pierre Gangneux; Philippe Montravers; Jean-Paul Mira; François Gouin; Jean-Pierre Sollet; Jean Carlet; Jacques Reynes; Michel Rosenheim; Bernard Regnier; Olivier Lortholary
Journal:  Crit Care Med       Date:  2009-05       Impact factor: 7.598

7.  Epidemiology, species distribution, antifungal susceptibility, and outcome of candidemia across five sites in Italy and Spain.

Authors:  Matteo Bassetti; Maria Merelli; Elda Righi; Ana Diaz-Martin; Eva Maria Rosello; Roberto Luzzati; Anna Parra; Enrico Maria Trecarichi; Maurizio Sanguinetti; Brunella Posteraro; Jose Garnacho-Montero; Assunta Sartor; Jordi Rello; Mario Tumbarello
Journal:  J Clin Microbiol       Date:  2013-10-09       Impact factor: 5.948

Review 8.  Management of invasive candidiasis and candidemia in adult non-neutropenic intensive care unit patients: Part I. Epidemiology and diagnosis.

Authors:  Benoît P Guery; Maiken C Arendrup; Georg Auzinger; Elie Azoulay; Márcio Borges Sá; Elizabeth M Johnson; Eckhard Müller; Christian Putensen; Coleman Rotstein; Gabriele Sganga; Mario Venditti; Rafael Zaragoza Crespo; Bart Jan Kullberg
Journal:  Intensive Care Med       Date:  2008-10-30       Impact factor: 17.440

9.  Septic shock due to candidemia: outcomes and predictors of shock development.

Authors:  Jorge A Guzman; Ronny Tchokonte; Jack D Sobel
Journal:  J Clin Med Res       Date:  2011-04-04

10.  Anidulafungin compared with fluconazole for treatment of candidemia and other forms of invasive candidiasis caused by Candida albicans: a multivariate analysis of factors associated with improved outcome.

Authors:  Annette C Reboli; Andrew F Shorr; Coleman Rotstein; Peter G Pappas; Daniel H Kett; Haran T Schlamm; Arlene L Reisman; Pinaki Biswas; Thomas J Walsh
Journal:  BMC Infect Dis       Date:  2011-09-30       Impact factor: 3.090

View more
  97 in total

1.  Evaluation of candidemia and antifungal consumption in a large tertiary care Italian hospital over a 12-year period.

Authors:  Jessica Mencarini; Elisabetta Mantengoli; Lorenzo Tofani; Eleonora Riccobono; Rossella Fornaini; Filippo Bartalesi; Giampaolo Corti; Alberto Farese; Patrizia Pecile; Luca Boni; Gian Maria Rossolini; Alessandro Bartoloni
Journal:  Infection       Date:  2018-04-13       Impact factor: 3.553

2.  Are prophylactic antifungals in highly colonized patients safe and effective?

Authors:  Matteo Bassetti; Cristobal Leon; Jean Francois Timsit
Journal:  Intensive Care Med       Date:  2015-06-03       Impact factor: 17.440

3.  Intra-abdominal candidiasis: it's still a long way to get unquestionable data.

Authors:  Philippe Montravers; Olivier Leroy; Christian Eckmann
Journal:  Intensive Care Med       Date:  2015-06-19       Impact factor: 17.440

4.  Comparative evaluation of a new commercial colorimetric microdilution assay (SensiQuattro Candida EU) with MIC test strip and EUCAST broth microdilution methods for susceptibility testing of invasive Candida isolates.

Authors:  Hedda Luise Koehling; Birgit Willinger; Jan Buer; Peter-Michael Rath; Joerg Steinmann
Journal:  J Clin Microbiol       Date:  2014-11-12       Impact factor: 5.948

Review 5.  Management of invasive candidiasis in nonneutropenic ICU patients.

Authors:  Emmanuel Weiss; Jean-François Timsit
Journal:  Ther Adv Infect Dis       Date:  2014-10

6.  Inhibition of antifungal therapy by gastric acid suppressants.

Authors:  Harry W Daniell
Journal:  Intensive Care Med       Date:  2015-02-21       Impact factor: 17.440

7.  Acid-suppressant therapy does not influence absorption of azoles used in candidemia.

Authors:  Bruno Viaggi; Carlo Tascini; Francesco Menichetti
Journal:  Intensive Care Med       Date:  2015-02-21       Impact factor: 17.440

8.  Risk factors and predictors of mortality of candidaemia among critically ill patients: role of antifungal prophylaxis in its development and in selection of non-albicans species.

Authors:  Matthaios Papadimitriou-Olivgeris; Anastasia Spiliopoulou; Fotini Fligou; Iris Spiliopoulou; Lora Tanaseskou; Georgios Karpetas; Markos Marangos; Evangelos D Anastassiou; Myrto Christofidou
Journal:  Infection       Date:  2017-07-29       Impact factor: 3.553

9.  Multicenter evaluation of Candida QuickFISH BC for identification of Candida species directly from blood culture bottles.

Authors:  Ayman M Abdelhamed; Sean X Zhang; Tonya Watkins; Margie A Morgan; Fann Wu; Rebecca J Buckner; DeAnna D Fuller; Thomas E Davis; Hossein Salimnia; Marilynn R Fairfax; Paul R Lephart; Melinda D Poulter; Sarah B Regi; Michael R Jacobs
Journal:  J Clin Microbiol       Date:  2015-03-11       Impact factor: 5.948

10.  Impact of Loading Dose of Caspofungin in Pharmacokinetic-Pharmacodynamic Target Attainment for Severe Candidiasis Infections in Patients in Intensive Care Units: the CASPOLOAD Study.

Authors:  Sébastien Bailly; Elodie Gautier-Veyret; Minh P Lê; Lila Bouadma; Olivier Andremont; Mathilde Neuville; Bruno Mourvillier; Romain Sonneville; Eric Magalhaes; Jordane Lebut; Aguila Radjou; Roland Smonig; Michel Wolff; Laurent Massias; Claire Dupuis; Jean-François Timsit
Journal:  Antimicrob Agents Chemother       Date:  2020-11-17       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.